Cargando…

Financing equitable access to antiretroviral treatment in South Africa

BACKGROUND: While South Africa spends approximately 7.4% of GDP on healthcare, only 43% of these funds are spent in the public system, which is tasked with the provision of care to the majority of the population including a large proportion of those in need of antiretroviral treatment (ART). South A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleary, Susan, McIntyre, Di
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895746/
https://www.ncbi.nlm.nih.gov/pubmed/20594368
http://dx.doi.org/10.1186/1472-6963-10-S1-S2
_version_ 1782183287242883072
author Cleary, Susan
McIntyre, Di
author_facet Cleary, Susan
McIntyre, Di
author_sort Cleary, Susan
collection PubMed
description BACKGROUND: While South Africa spends approximately 7.4% of GDP on healthcare, only 43% of these funds are spent in the public system, which is tasked with the provision of care to the majority of the population including a large proportion of those in need of antiretroviral treatment (ART). South Africa is currently debating the introduction of a National Health Insurance (NHI) system. Because such a universal health system could mean increased public healthcare funding and improved access to human resources, it could improve the sustainability of ART provision. This paper considers the minimum resources that would be required to achieve the proposed universal health system and contrasts these with the costs of scaled up access to ART between 2010 and 2020. METHODS: The costs of ART and universal coverage (UC) are assessed through multiplying unit costs, utilization and estimates of the population in need during each year of the planning cycle. Costs are from the provider’s perspective reflected in real 2007 prices. RESULTS: The annual costs of providing ART increase from US$1 billion in 2010 to US$3.6 billion in 2020. If increases in funding to public healthcare only keep pace with projected real GDP growth, then close to 30% of these resources would be required for ART by 2020. However, an increase in the public healthcare resource envelope from 3.2% to 5%-6% of GDP would be sufficient to finance both ART and other services under a universal system (if based on a largely public sector model) and the annual costs of ART would not exceed 15% of the universal health system budget. CONCLUSIONS: Responding to the HIV-epidemic is one of the many challenges currently facing South Africa. Whether this response becomes a “resource for democracy” or whether it undermines social cohesiveness within poor communities and between rich and poor communities will be partially determined by the steps that are taken during the next ten years. While the introduction of a universal system will be complex, it could generate a health system responsive to the needs of all South Africans.
format Text
id pubmed-2895746
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28957462010-07-03 Financing equitable access to antiretroviral treatment in South Africa Cleary, Susan McIntyre, Di BMC Health Serv Res Research BACKGROUND: While South Africa spends approximately 7.4% of GDP on healthcare, only 43% of these funds are spent in the public system, which is tasked with the provision of care to the majority of the population including a large proportion of those in need of antiretroviral treatment (ART). South Africa is currently debating the introduction of a National Health Insurance (NHI) system. Because such a universal health system could mean increased public healthcare funding and improved access to human resources, it could improve the sustainability of ART provision. This paper considers the minimum resources that would be required to achieve the proposed universal health system and contrasts these with the costs of scaled up access to ART between 2010 and 2020. METHODS: The costs of ART and universal coverage (UC) are assessed through multiplying unit costs, utilization and estimates of the population in need during each year of the planning cycle. Costs are from the provider’s perspective reflected in real 2007 prices. RESULTS: The annual costs of providing ART increase from US$1 billion in 2010 to US$3.6 billion in 2020. If increases in funding to public healthcare only keep pace with projected real GDP growth, then close to 30% of these resources would be required for ART by 2020. However, an increase in the public healthcare resource envelope from 3.2% to 5%-6% of GDP would be sufficient to finance both ART and other services under a universal system (if based on a largely public sector model) and the annual costs of ART would not exceed 15% of the universal health system budget. CONCLUSIONS: Responding to the HIV-epidemic is one of the many challenges currently facing South Africa. Whether this response becomes a “resource for democracy” or whether it undermines social cohesiveness within poor communities and between rich and poor communities will be partially determined by the steps that are taken during the next ten years. While the introduction of a universal system will be complex, it could generate a health system responsive to the needs of all South Africans. BioMed Central 2010-07-02 /pmc/articles/PMC2895746/ /pubmed/20594368 http://dx.doi.org/10.1186/1472-6963-10-S1-S2 Text en Copyright ©2010 Cleary and McIntyre; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Cleary, Susan
McIntyre, Di
Financing equitable access to antiretroviral treatment in South Africa
title Financing equitable access to antiretroviral treatment in South Africa
title_full Financing equitable access to antiretroviral treatment in South Africa
title_fullStr Financing equitable access to antiretroviral treatment in South Africa
title_full_unstemmed Financing equitable access to antiretroviral treatment in South Africa
title_short Financing equitable access to antiretroviral treatment in South Africa
title_sort financing equitable access to antiretroviral treatment in south africa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895746/
https://www.ncbi.nlm.nih.gov/pubmed/20594368
http://dx.doi.org/10.1186/1472-6963-10-S1-S2
work_keys_str_mv AT clearysusan financingequitableaccesstoantiretroviraltreatmentinsouthafrica
AT mcintyredi financingequitableaccesstoantiretroviraltreatmentinsouthafrica